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Background. People with Prader–Willi syndrome (PWS), a genetically deﬁned developmental disorder, are at increased
risk of developing psychotic illness. This is particularly the case for those with a genetic subtype of PWS called maternal
uniparental disomy (mUPD), where rates of psychosis are more than 60% by early adult life. Little is known about the
long-term course of their disorder.
Method. Individuals who had had episodes of psychosis or were at increased risk of developing psychosis due to their
genetic subtype and had taken part in a previous study were contacted. Ten people were untraceable or deceased, leav-
ing a total of 38 potential participants. Of these, 28 agreed to take part in a follow-up interview or complete a question-
naire about their mental health and medication. This represented 20/35 (57.1%) people from the original study who had
had psychosis and 8/13 (61.5%) people who were at risk due to their genetic subtype. They were thought to be represen-
tative of those groups as a whole based on IQ and number of episodes of psychosis.
Results. Two individuals had had recurrent episodes of psychosis while all others remained well. There were no new-
onset cases of psychosis in those at risk. Individuals with PWS remained on high levels of psychiatric medication
throughout the follow-up period.
Conclusions. Recurrent episodes of psychosis may be rare in people with PWS once stability has been achieved in the
management of their illness. We speculate that this may be due to the protective inﬂuence of medication.
Received 23 May 2013; Revised 30 July 2013; Accepted 12 November 2013; First published online 13 December 2013
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Introduction
Studies have established that people with the
genetically determined neurodevelopmental disorder
Prader–Willi syndrome (PWS) are at an increased risk
for developing affective disorders and psychotic illness
in late childhood and early adult life (Vogels et al. 2004;
Soni et al. 2007, 2008; Sinnema et al. 2011). Psychosis is
particularly common in a subgroup of people with
PWS who have a duplication of the maternal copy of
chromosome 15 and an absence of the paternal copy
(referred to as maternal uniparental disomy, or
mUPD), with 60–100% developing mUPD by early
adult life. This contrasts with approximately 20% of
those with PWS due to the other main genetic cause
of PWS, an interstitial deletion of a section of the
paternal copy of chromosome 15 (15q11–q13) (delPWS)
(Boer et al. 2002; Soni et al. 2007; Sinnema et al. 2011).
Phenomenologically, the psychotic illness does not ﬁt
clearly into an affective or a schizophrenic illness and
has been more closely likened to a cycloid psychosis.
Little is known about the course of the disorder (see
Soni et al. 2007). The aim of this study was therefore
to follow up all people from the Soni et al. (2007,
2008) sample who met the criteria for psychosis, in ad-
dition to following up the most at-risk group, that is
people with mUPDwho had not experienced psychosis
at the time of the original study. It is assumed that the
psychosis experienced by these individuals is the cyc-
loid, PWS-speciﬁc psychosis rather than a more general
psychosis due to other factors, based on descriptions of
the illness given by Soni et al. (2007, 2008).
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Attempts were made to contact 48 people with PWS
identiﬁed as having had a psychotic illness and seen
as part of the original study by Soni et al. (2007) and
also those with PWS due to mUPD who had not
been psychotic. Twenty people agreed to participate
in an interview about their mental health and a further
eight completed a postal questionnaire about their
mental health since their involvement in the last
study, followed up by a telephone conversation with
a nominated informant. Table 1 summarizes the re-
sponse rates.
A structured interview schedule was designed
to elicit and record details of participants’ mental
health since their last study involvement. Information
was sought from both an informant and the partici-
pants themselves about the overall state of the partici-
pants’ mental health since their involvement in the
previous study, including the number of psychotic
episodes, number of hospitalizations for mental health
reasons, symptoms during any psychotic episodes, and
details of current psychiatric medication. Information
was also sought about their functioning in the past
4 weeks, including information about the quality of
relationships, activities, presence of psychiatric symp-
toms, challenging behaviour and self-care. Based on
this, a global assessment of functioning (GAF) score
(Hall, 1995) was assigned by a trained rater (F.V.L.)
as a representation of current functioning.
Data analysis
The distribution of IQ and GAF scores was checked
and found to be normal. Categorical data were
assigned numerical values for analysis. Medication
was considered as both a continuous and a categorical
variable by listing the number of different medications
people were currently taking and constructing categor-
ies regarding types of medication prescribed to indi-
viduals. GAF scores of people who had experien-
ced further psychotic episodes were compared with
those who had not, using an independent-samples
t test. Additionally, the GAF scores of people who
had experienced psychosis were compared between
the groups with delPWS and mUPD using an in-
dependent-samples t test, after conﬁrming there were
no differences in IQ between those two groups.
Descriptive statistics were used to describe medi-
cation proﬁles. Change in medication over time was
assessed by χ2 analysis. A change was considered to
have taken place if a participant had stopped taking
a medication, started a new medication, or both.
Results
Cause of death was known for three of the six partici-
pants who had died. The age of death ranged from 20
to 58 years and none were known to be as a result of
suicide.
Relapse of illness
Mood instability and behavioural problems still fea-
tured in carer and self-reports of difﬁculties, consistent
with the well-described PWS behavioural phenotype
(Holland et al. 2003). Nevertheless, participants and
their carers reported good mental health since involve-
ment in the original study. Two of the 20 (10%) who
had previously been psychotic had had a deﬁnite
recurrence of psychosis, and a further participant
reported hearing voices regularly but was functioning
well despite this. No one with mUPD who had not
previously been psychotic had developed a psychotic
illness during this period.
Out of the 20 people we were able to follow-up who
had experienced psychosis, 13 had only had one epi-
sode at the time of the original study, with an even
spread between those with mUPD and delPWS.
Those who chose not to take part or who had died/
were untraceable had experienced a similar range of
number of episodes (in both cases, range 1–5, means
2.15 for the follow-up group and 2.33 for rest).
Table 1. Summary of status of all participants who were contacted as part of this follow-up study by presence or absence of psychosis and
genetic subtype of Prader–Willi syndrome (PWS)
Emigrated Deceased Untraceable Declined Interviewed
Responded
to questionnaire
mUPD, never psychotic (n=12) 0 2 1 1 6 2
mUPD, psychotic (n=22) 1 2 1 7 7 4
delPWS, psychotic (n=14) 0 2 1 2 7 2
Total 1 6 3 10 20 8
mUPD, PWS caused by maternal uniparental disomy; delPWS, PWS caused by a deletion of a section of the paternal copy
of chromosome 15q11-q13.
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Medication
We compared psychiatric medication at the time of
the original study, the follow-up 1 year later and our
follow-up, an average of 5.5 years later. The majority
of participants were prescribed psychotropic medi-
cation (18/28; 64.3%). Ten of these were taking more
than one type of medication. Only one person who
had never had psychosis had a change in psychiatric
medication. Two people who had never been psychotic
were maintained on selective serotonin reuptake inhibi-
tors (SSRIs) at all stages of their involvement in the
study. Figure 1 shows a summary of current medication
prescriptions for all participants in this follow-up study.
Of the people who had been psychotic, the picture
was more mixed. Thirteen people had had signiﬁcant
changes to their medication since the last follow-up
whereas seven had had their medication maintained
during follow-up. People who had been psychotic
had signiﬁcantly more medication changes than those
who had not (χ2=5.34, p=0.03).
Only two participants who had had psychosis were
taken off medication completely by the time of this
study; all others were maintained on at least one
kind of medication. Additionally, two people who
had a history of psychosis were not on medication at
the time of the original study or this follow-up.
Outcome
There was no signiﬁcant relationship between GAF
score and IQ (r=–0.214, p=0.366). People who had
never been psychotic had a signiﬁcantly better out-
come than those who had (t=2.99, df=26, p=0.006).
Discussion
More than half of the group who originally had psy-
chotic illness at the time of the Soni et al. (2007, 2008)
study were interviewed. It is possible that the subset
of people who chose not to take part in the follow-up
study or were not traceable may not have been func-
tioning as well and/or had higher rates of relapse.
However, only 10% of the population studied here
had relapsed, which indicates to us stability in the
course of the psychotic illness in people with PWS
generally, certainly over the medium term. Further
follow-up would be required to make any claims
about long-term well-being, but our prediction would
be that relapse rates would continue to be low into
the future and that psychiatric outcome could gener-
ally be considered good for those who had psychosis.
The continued well-being of people with mUPD
who had never been psychotic hints at the possibility
of a window of risk, similar to that seen in people
with psychosis in the general population. The age of
risk ranges up to the late 40 s/early 50 s for schizo-
phrenia and into the 70 s for affective psychoses
(Slater & Cowie, 1971). The age of risk is unknown
for people with PWS, but data from Soni et al. (2008)
indicate that it may be broadly similar to that of the
general population (the oldest onset reported in that
study was age 40 years, with average age at onset in
Fig. 1. Types of medication prescribed to participants with Prader–Willi syndrome (PWS) at the time of this follow-up study.
SSRI, Selective serotonin reuptake inhibitor; AP, antipsychotics; MS, mood stabilizers. Percentages of the total for each group
are shown.
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the late teens). Thus, it is worth noting that the people
with mUPD studied here remain at risk of developing
psychosis. Further follow-up study would be required
to begin to determine whether this is the case, although
the shorter lifespan and higher mortality rates of indi-
viduals with PWS (Whittington & Holland, 2004) may
make follow-up impossible into later middle age. In
line with this, the average age of the six people who
died in the follow-up period was 36.6 years.
A stress–vulnerability model may be appropriate in
considering these ﬁndings. Our hypothesis is that of
a ’two-hit’ model. First, for most people with PWS,
having PWS itself increases the risk for affective dis-
order in general, one candidate gene being the small
nucleolar (sno)RNA HBIII-52, which negatively regu-
lates editing and alternative splicing of the serotonin
2C receptor (5-HT2cR) pre-RNA (Doe et al. 2009). In
mouse knock-out models, pharmacological challenges
support the view that behavioural changes observed
may be due to 5-HT2CR dysfunction (Doe et al. 2009).
The second hit we hypothesize is due to the excess ex-
pression of a gene of the opposite imprint to the PWS
gene(s) (i.e. the maternal copy is expressed and the pa-
ternal copy silenced). We propose that this increases
the risk of psychotic illness. Thus, this combination
makes people with PWS due to mUPD, or due to a
deletion but with extra genetic material, more vulner-
able to having a psychotic episode (Webb et al. 2008).
We suggest that the high rates of prescription of anti-
psychotic, antidepressant and mood-stabilizing medi-
cation are potentially moderating this vulnerability,
perhaps by addressing the mood instability that
people with PWS are prone to. It seems to us that
the reduction in the size of the highs and lows in
people with PWS is important in preventing
psychosis, given the prevalence of mood-related symp-
toms at onset (Soni et al. 2007, 2008). It is not known
what the outcome for people would be if they were re-
moved from medication entirely, but it seems a reason-
able assumption that medication would be under
review regularly and attempts would have been
made to reduce medication if it were possible to do
this without adversely affecting the participants’
mental health.
A potential criticism of the current study is that no
formalized outcome measure was used. However, par-
ticipants and their carers were given their original epi-
sode of illness as a reference point and it is clear that, in
those who reported no further episodes, nothing of
similar psychiatric signiﬁcance had occurred. The sign-
iﬁcant psychotic episodes reported in two individuals
in the intervening period were different in terms of
duration and course, but both contained elements of
mood instability, with symptoms of both depression
and mania. One seems to be a more recurring mental
health problem whereas the other has thus far been
an isolated, albeit longer-lasting, event. One of these
individuals has seen her medication changed signiﬁ-
cantly over the follow-up period whereas the other
has persisted on the same medication with only the
dose altered. It is unclear why these two people be-
came unwell when so many others did not, and this
may be due to a combination of biological, psychologi-
cal and social factors that would be difﬁcult to fully
quantify.
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